Cell migration is an integral component of metastatic disease. The ability of cells to transit between mesenchymal and amoeboid modes of migration has complicated the development of successful therapies designed to target cell migration as a means of inhibiting metastasis. Therefore, investigations of the mechanisms that regulate cell migration and render cells stationary are necessary. Tropomyosins are actin-associating proteins that regulate the activity of several effectors of actin filament dynamics. Previously, we have shown that the tropomyosin isoform Tm5NM1 stabilizes actin filaments and inhibits cell migration in a two-dimensional culture system. Here, we show that Tm5NM1 inhibits the mesenchymal migration of multiple cell lines in an isoform-specific manner. Tm5NM1 stimulates the downregulation of Src kinase activity and a rounded or elliptical morphology in threedimensional collagen gels, and cells have dramatically reduced capacity to form pseudopodia. Importantly, we find that Tm5NM1 inhibits both the mesenchymal to amoeboid and amoeboid to mesenchymal transitions. Collectively, our data suggest that mimicking the action of Tm5NM1 overexpression represents an approach for effectively inhibiting the mesenchymal mode of migration.
Introduction
Metastatic disease is the leading cause of cancer-related mortality (Fidler, 2002) . During the initial stages of metastasis, cancer cells migrate away from the primary tumour site through surrounding tissue and towards nearby vasculature and lymph vessels. Following successful invasion and migration, tumour cells progress to secondary sites and establish ectopic tumour growth. This results in a range of associated pathologies that ultimately lead to the death of the patient (Poste and Fidler, 1980) . Owing to the critical role of invasion and migration in metastasis, there has been considerable interest in targeting cancer cells' migration machinery as a novel therapeutic approach. However, it has become clear that cancer cells use a range of motility modes to migrate and invade (Friedl, 2004) . Indeed the ability of cancer cells to switch between motility modes has likely contributed to the low efficacy of some anti-metastatic therapies (Kruger et al., 2001; Coussens et al., 2002) . Cellular mechanisms that inhibit cell motility and render a cell stationary require further investigation, as these mechanisms have obvious benefits for the advancement of therapeutic approaches in treating metastatic cancers.
Distinct individual cell motility modes, termed mesenchymal and amoeboid migration, have been revealed through the use of in vivo and three-dimensional (3D) collagen gel culture systems . Mesenchymal migration is characterized by cell elongation and branching polarized protrusions in the direction of migration. The chief properties that define mesenchymal migration include activation of the small GTPase Rac (Sanz-Moreno et al., 2008; Yamazaki et al., 2009) , targeted expression of matrix metalloproteases (Sahai and Marshall, 2003; Wolf et al., 2003) and the regulated formation and disassembly of integrin receptor-mediated extracellular matrix adhesions mediated by the activity of Src kinase Carragher et al., 2006) . In contrast, amoeboid migration is characterized by rounded cell morphology and is associated with non-apoptotic plasma membrane blebbing (Sahai and Marshall, 2003) . Rapid expansion and contraction allow amoeboid cells to squeeze through obstructing matrix, and this is highly dependant on actomyosin contractility (Sahai and Marshall, 2003; Sanz-Moreno et al., 2008; Friedl and Wolf, 2010) . The migration of amoeboid cells is facilitated by the RhoA GTPase effector molecule Rho-associated kinase (ROCK), independent of matrix metalloprotease activity and less dependant on integrin receptor adhesion to the extracellular matrix (Friedl and Wolf, 2003, 2010; Carragher et al., 2006) . Many cells are competent to undergo transition between mesenchymal and amoeboid migration modes (Carragher et al., 2006; Yamazaki et al., 2009) , and manipulating the principle molecular regulators can induce cells to switch between these modes. Thus, blocking mesenchymal migration by treatment with protease inhibitors (PIs) or blocking Rac activity (Sanz-Moreno et al., 2008) causes cells to switch to an amoeboid motility mode. Notably, cell migration speeds are unaffected following mesenchymal to amoeboid transition . Conversely, RhoA/Rho-associated kinase inhibition inhibits amoeboid migration by switching cells from an amoeboid to a mesenchymal mode (Yamazaki et al., 2009) .
The tropomyosin family of actin-associating proteins has emerged as important determinant of cell migration (Bryce et al., 2003; Gupton et al., 2005; Bach et al., 2009; O'Neill 2009 ). This multi-isoform family of proteins primarily form lateral in register homodimers, depending on the isoform, additionally form head-to-tail polymers and lay in the major groove of polymerized actin filaments (Gunning et al., 2008) . Association of particular tropomyosin isoforms with actin filaments in turn regulates the association of molecules that determine the dynamics of actin filament turnover (Ishikawa et al., 1989; Blanchoin et al., 2001; Bryce et al., 2003) . Tropomyosin isoform Tm5NM1 stimulates increased actin stress fibre formation by enhancing the stability of associated actin filaments, leading to inhibited cell migration in two-dimensional (2D) cultures (Bryce et al., 2003; Creed et al., 2008; Bach et al., 2009) . Importantly, expression of this isoform can vary up to 5-fold between different tissues, with the highest levels observed in lung tissue . Furthermore, we have previously demonstrated that Tm5NM1-mediated stabilization of the actin filaments causes significant inhibition of focal adhesion disassembly (Bach et al., 2009) . Given that focal adhesion turnover is required for mesenchymal migration, these results suggested that Tm5NM1 might specifically block mesenchymal migration. Moreover, increased myosin IIA activity in cells overexpressing Tm5NM1 (Bryce et al., 2003) and the association between amoeboid movement and actomyosin contractility (Sahai and Marshall, 2003; SanzMoreno et al., 2008) warrant investigation of the role Tm5NM1 plays in cell migration. To date, the role of Tm5NM1 in these physiological migration modes has not been investigated.
In the present study, we sought to address the role of Tm5NM1 in mesenchymal and amoeboid motility using 3D collagen matrices and a range of cancer cell lines with mesenchymal and amoeboid phenotypes. We find that Tm5NM1 overexpression significantly inhibits mesenchymal migration in multiple cell lines. Importantly, Tm5NM1-mediated inhibition of mesenchymal migration is not accompanied by a transition to amoeboid migration. Thus, our studies suggest that mimicking the action of Tm5NM1 overexpression may represent a method to arrest the movement of tumour cells migrating in a mesenchymal mode.
Results

Tm5NM1 inhibits mesenchymal migration
To test the hypothesis that Tm5NM1 inhibits mesenchymal migration, we analyzed cells seeded within 3D collagen matrices and used time-lapse imaging to monitor morphology and speed of migrating cells. Control B35 neuroblastoma cells displayed an elongated branching morphological characteristic of mesenchymal cells within 3D matrices (Figure 1a) . In contrast, B35 cells stably overexpressing B5-fold higher levels of Tm5NM1 (B35.Tm5NM1) (Figure 1b) were predominantly elliptical with numerous short, pericellular protrusions ( Figure 1c) . Agreeing with our earlier report that Tm5NM1 reduces migration speed of cells in 2D culture systems (Bach et al., 2009) , Tm5NM1 overexpression significantly reduces migration speed within 3D collagen gels (Figure 1d ). Indeed, B35.Tm5NM1 cells within 3D matrices are fundamentally stationary (speeds o0.05 mm/min represent cell oscillation rather than actual cell migration), and we observe very little translocation of cell bodies in these cultures. Importantly, apoptotic and mitotic cells were excluded from this and subsequent analyses. Moreover, greater than 85% of the B35 and B35.Tm5NM1 cells were viable within the 3D collagen gels (B35: 92% ± 6.0, B35.Tm5NM1: 85%±9.7), thus confirming that exogenously expressed Tm5NM1 does not cause defects in cell migration due to loss of cell viability. We separately tested the effect of Tm5NM1 overexpression on cellular invasion using a directional invasion assay. B35.Tm5NM1 cells demonstrated dramatically reduced levels of cell invasion when compared with controls ( Figure 1e ). 3D reconstructions show cells invading into the collagen gels and highlight the inability of Tm5NM1-overexpressing cells to invade the collagen gel ( Figure 1f) .
Observation of time-lapse movies suggested that B35 cells migrate within collagen matrices using a typical mesenchymal mode of motility with cell elongation and branching polarized protrusions in the direction of migration (Figure 1g and Supplementary Video 1), which was inhibited by Tm5NM1 overexpression (Figure 1c ). To specifically confirm that B35 cells move with a mesenchymal motility mode, we determined the consequences of inhibiting either Rac activity or matrix proteases. Both dominant-negative Rac and treatment with a cocktail of matrix PIs significantly decreased cell speed (Figures 1h and k) and caused cells to adopt a more rounded, less elongated morphology (Figures 1j  and m) . These results confirm that B35 cells migrate using a mesenchymal mode of motility. Significantly, Tm5NM1 overexpression similarly inhibits B35 cell migration ( Figure 1d ) and causes the cells to become elliptical ( Figure 1c and Supplementary Video 1), suggesting that Tm5NM1 inhibits mesenchymal cell migration.
Using fibroblasts derived from a mouse model lacking Tm5NM1 expression (Figure 2a) , we have previously established that the absence of Tm5NM1 expression promotes increased migration persistence in 2D assays of cell migration (Bach et al., 2009) . Thus, to confirm the role of Tm5NM1 in regulating mesenchymal cell migration, we assayed the behaviour of these cells in 3D collagen gels. We found that within 3D collagen gels the knockout fibroblasts have significantly faster rates of migration than their control counterparts ( Figure 2b ). Moreover, the cells retain their elongated phenotypes and continue to move through the gels in a mesenchymal manner ( Figure 2c ). It is notable that in contrast to these findings, in our earlier 2D assays of cells migration, we did not detect any significant changes in cell migration speeds (Bach et al., 2009) . Together, these data suggest that Tm5NM1 regulates mesenchymal cell speed under 3D culture conditions.
To confirm that the observed effects of Tm5NM1 overexpression can be generalized to cells of different derivation and origin, we employed the U-87 MG glioblastoma cell line, as this cell type is well established to migrate using a mesenchymal motility mode (Friedl, 2004; Yamazaki et al., 2009) . Importantly, Tm5NM1 significantly inhibited U-87 MG cell migration in 3D collagen gels accompanied by conversion to a less elongated morphology analogous to the Tm5NM1 phenotype stimulated in the B35 cells (Supplementary Figure 1) . Finally, the lack of effect on cell migration and morphology in cells expressing a second tropomyosin isoform, Tm3 (highest expressing clone described in Creed et al., 2008) , suggests that Tm5NM1 exerts isoform-specific effects on mesenchymal migration (Supplementary Figure 2 and Supplementary Video 2).
Tm5NM1-mediated changes to cell morphology and Src kinase activity A characteristic feature of mesenchymal migration in 3D cultures is the extension of long membrane processes in the direction of migration (as in Figure 1a ), referred to as pseudopodia (Friedl and Wolf, 2010) . We observed that the majority of the cells overexpressing Tm5NM1 failed to extend pseudopodia. Quantification of this observation (in which a pseudopodium was defined as a membrane extension at least 7 mm long and at least 1 mm thick) revealed that there was a 95% reduction in pseudopodia formation associated with Tm5NM1-overexpressing cells (Figure 3a) . Indeed, in contrast to the morphology of the B35 control cells, B75% of the B35.Tm5NM1 cells exhibited a rounded elliptical morphology. The remaining 25% of the cells displayed an elongated morphology, although these cells did not have obvious polarized pseudopodia and they were nonmotile. Instead, the elongated cells were observed to extend shorter processes from opposing ends, thus effectively holding the cells in place (Figure 3b and Supplementary Video 3).
We next determined the composition of the short pericellular protrusions, observed in the B35.Tm5NM1 cells (Figure 1c) , by transfecting the cells with GFPtagged monomeric LifeACT to detect filamentous actin (Riedl et al., 2008) . Confocal microscopy revealed that the short spikes emanating from the Tm5NM1-overexpressing cells are actin-rich structures, visible both in the main population of elliptical cells and the 25% of the elongated cells (Figures 3c and d) . In 3D reconstructions of confocal slices, these actin-rich spikes can be clearly seen protruding from all over the body of elliptical cells and predominately from the opposite ends of elongated cells (Supplementary Video 4) . In contrast, control cells show actin-rich aggregations along the length of the pseudopodia and extend a number of small actin-rich spikes at the end of the pseudopodia (Figure 3e ). In general, the B35 control cells had a significantly more elongated appearance than the B35.Tm5NM1 cells, spreading throughout a larger area of the 3D collagen gel. Measurement of the minimal gel volume that encompassed the entire cell (calculated using the longest xyz dimensions from images of a z-stack) revealed that the B35 total cell occupancy volume was approximately double that of the B35.Tm5NM1 cells (Figure 3f) .
We have previously reported that Tm5NM1 significantly suppresses focal adhesion dynamics in 2D cultures (Bach et al., 2009) , and observation of the cells overexpressing Tm5NM1 in 3D collagen gels suggests that these cells are tightly connected to the surrounding collagen (Supplementary Video 1). As Src kinase is a major regulator of focal adhesion stability and mesenchymal motility (Fincham and Frame, 1998; Webb et al., 2004; Carragher et al., 2006) , and we have demonstrated that total Src expression is decreased in cells with elevated Tm5NM1 (Bach et al., 2009 ), we next tested whether Src kinase activity is suppressed. Using antibodies to the activated form of Src kinase, we find significantly decreased activated Src, relative to total Src protein in cells with elevated Tm5NM1 (Figures 3g and h) . Downregulation of Src kinase activity was separately confirmed by in vitro Src kinase assay, and knockdown of exogenous Tm5NM1 restored Src activity levels (Figures 3i and j) . Thus, elevated Tm5NM1 expression appears to suppress Src kinase activity.
Tm5NM1 blocks mesenchymal to amoeboid transition
We then determined the role of Tm5NM1 in the transition between mesenchymal and amoeboid phenotypes by using the HT1080 fibrosarcoma cell line that readily transits between the two motility modes (Wolf et al., 2003) . Importantly, we first confirmed that Tm5NM1 incorporates into the HT1080 cell stress fibres (Supplementary Figure 3A) , as established above for B35 and U-87 MG cells and previously demonstrated in fibroblasts (Bach et al., 2009) . Moreover, western blot analysis confirmed robust expression of exogenous YFP.Tm5NM1 (Supplementary Figure 3B) . Agreeing with earlier findings , B50% of the HT1080 cells display an elongated, mesenchymal morphology in collagen gels (Figures 4a and b) . Treatment with PI essentially abrogates this mesenchymal population (Figures 4a and c) ,and transfection with YFP-tagged Tm5NM1 similarly caused a significant decrease in the percentage of cells displaying an elongated morphology (Figures 4a and d) . As both PI-treated and Tm5NM1-expressing cells lost their mesenchymal morphology, we questioned whether both treatments had caused cells to undergo amoeboid transition. As expected, PI-treated cells had equivalent cell speed to their control counterparts, indicating that they had indeed transitioned to an amoeboid-invasion mode (Figure 4e and Supplementary Video 5). The appearance of characteristic amoeboid morphologies subsequent to PI addition confirms that this was not due to failure of the inhibitors (Figure 4c) . Critically, in contrast to PI treatment, exogenous Tm5NM1 expression significantly suppressed migration speed of Figure 4e ). Thus, in contrast to PI treatment, which causes transition to amoeboid migration, our data suggest that Tm5NM1 stimulates cells with a mesenchymal phenotype to transit to a non-invasive phenotype.
HT1080 (
Tm5NM1 blocks amoeboid to mesenchymal transition Next, we questioned whether Tm5NM1 could block the transition from an amoeboid to a mesenchymal state. To test this, we took advantage of the fact that Rho kinase inhibition causes amoeboid cells to adopt a characteristic elongated cell shape, extending multiple cellular processes out from the cell body ( (Figures 5a and b) . Thus, these data support the suggestion that Tm5NM1 blocks the conversion of amoeboid cells to a mesenchymal phenotype.
Tm5NM1 does not inhibit amoeboid migration
A separate question raised by these findings is whether Tm5NM1 blocks the migration of amoeboid cells. To test this, we transitioned the HT1080 population to an amoeboid migration mode by treatment with PI and then determined whether Tm5NM1 overexpression inhibited amoeboid cell migration. Importantly, we found that Tm5NM1 overexpression did not reduce the migration speed of HT1080 cells under these conditions (Figures 6a and b and Supplementary Video 7). Co-treatment of HT1080.YFP cells with PI and Y-27632 confirmed that it is possible to inhibit migration of the amoeboid population (Figures 6a and  c) . Thus, although Tm5NM1 prevents amoeboid cells from transitioning to a mesenchymal phenotype, it does not inhibit established amoeboid migration in HT1080 cells.
Tm5NM1-mediated morphologies are distinct from amoeboid morphologies
Finally, given our data that Tm5NM1 does not stimulate amoeboid transition, yet does cause cells to adopt a rounded shape, we further investigated the Tm5NM1-stimulated cell morphologies. The morphologies of non-elongated HT1080 cells were in two broad categories that we classified as either amoeboid (Figure 7a ) or elliptical (Figure 7b ). Amoeboid cells were amorphic, underwent rapid contortion and migrated with considerable speed. Elliptical cells had a rounded morphology and were noticeably less motile. Cells were also observed to be capable of transitioning between these two morphological categories. Treatment of HT1080 cells with Y-27632 caused reductions in both the elliptical and the amoeboid cell populations (Figure 7c) , and a corresponding increase in the percentage of elongated cells (Figure 5a ). As expected, co-treatment with PI caused a significant increase in the (Figure 7c ). These data therefore indicate that amoeboid and elliptical cells differentially respond to PI treatment versus Tm5NM1 expression, confirming that they are two distinct cellular phenotypes. Moreover, these data suggest that indeed Tm5NM1 expression more efficiently blocks mesenchymal cell phenotypes than treatment with PIs.
Discussion
In this study we establish that Tm5NM1 inhibits mesenchymal migration. We found that the number of pseudopodia per cell is greatly reduced in Tm5NM1-overexpressing cells, and physical expansion of the actin cytoskeleton is fundamentally restricted when compared with control cells. Moreover, we show that Tm5NM1 blocks mesenchymal migration without concomitant transition to amoeboid motility, therefore, inhibiting the mesenchymal phenotype more efficiently than treatment with PIs. Hence, our study poses actin-associating molecules, such as the tropomyosins, as important regulators of the switch from a mesenchymal to a stationary phenotype.
Rac GTPase activity critically regulates pseudopodial protrusions and mesenchymal cell migration in 3D gels (Sanz-Moreno et al., 2008; Friedl and Wolf, 2010) , separately confirmed in the cell lines used in the present study by the use of dominant-negative Rac. Downstream from Rac, Arp2/3 initiates short-branched actin filaments that push against the cell membrane, leading to membrane protrusion. Arp2/3 function is further regulated by the activity of molecules, such as ADF/ cofilin that severs actin filaments creating new sites for Arp2/3-mediated actin branching. As tropomyosin association with actin filaments can block ADF/cofilin and Arp2/3 activity, it has been proposed that tropomyosin exclusion from the leading edge of migrating cells may create a zone of ADF/cofilin and Arp2/3 activity (DesMarais et al., 2002; Gupton et al., 2005) . Importantly, Tm5NM1 has been shown to compete with ADF/cofilin for binding to actin filaments (reviewed in Gunning et al., 2005) ; although this may not be the case for all tropomyosin isoforms (Bryce et al., 2003; Schevzov et al., 2005; Hillberg et al., 2006) . In contrast to the stabilization of actin filaments observed following elevated Tm5NM1 expression, elevated Tm3 expression sensitizes actin filaments to destabilization by actin depolymerizing drugs (Creed et al., 2008) . Correspondingly, in the present study, we demonstrate that Tm3 expression does not inhibit mesenchymal migration. Thus, saturation of actin filaments with Tm5NM1 may block the localization of ADF/cofilin, in turn preventing the protrusion of pseudopodia.
One of the defining features of mesenchymal cell motility is the requirement for regulated focal adhesion formation and disassembly Carragher et al., 2006) . Mounting evidence suggests that the expression profile of tropomyosin isoforms is an important determinant of focal adhesion structure and function (Gupton et al., 2005; Zheng et al., 2008; Bach et al., 2009; Drappatz et al., 2009; O'Neill, 2009) , and we have shown that elevated Tm5NM1 expression induces focal adhesion stabilization (Bach et al., 2009) . In 3D collagen gels, both control and Tm5NM1-expressing cells appear to be connected to the surrounding collagen as they pull on and deform the matrix (Supplementary Video 1), therefore, suggesting that these cells are adhered to the collagen matrix. Src kinase is a major regulator of focal adhesion stability (Fincham and Frame, 1998; Webb et al., 2004) , and Src inhibition specifically blocks mesenchymal motility (Carragher et al., 2006) . Related to this, we have previously shown that Src expression is suppressed in cells with elevated Tm5NM1 (Bach et al., 2009) , and in the present study, we establish that Src activity is significantly suppressed in cells with elevated Tm5NM1. Therefore, reduced Src activity following elevated Tm5NM1 expression may contribute to reduced focal adhesion dynamics and thus reduced mesenchymal cell migration.
Given the critical role of actomyosin contractility in amoeboid migration (Wyckoff et al., 2006) , together with the fact that Tm5NM1 causes increased myosin II activity (Bryce et al., 2003) , it is surprising that Tm5NM1 does not cause cells to transit to an amoeboid phenotype. Importantly, amoeboid motility is highly dependant on extensive reorganization of the actin cytoskeleton (Eichinger et al., 1999; Sahai, 2007; Kitzing et al., 2010) . We have shown that elevated Tm5NM1 causes reduced sensitivity to agents that reorganize the actin cytoskeleton (Bryce et al., 2003; Creed et al., 2008) , therefore, Tm5NM1 may block the dynamic response of the cytoskeleton that is required to switch to amoeboid type motility. However, in light of this, it is intriguing that Tm5NM1 does not block amoeboid motility. The answer may lie in the observation that protease inhibitor-stimulated transition to an amoeboid phenotype is accompanied by significantly reduced adhesion (Carragher et al., 2006) . We have shown that elevated Tm5NM1 expression specifically increases the formation of ventral actin stress fibres anchored by adhesions at either end and further anchored to the extracellular matrix by fibrillar adhesions along the length of the bundled actin filaments (Bach et al., 2009) . As the disassembly of cell adhesions causes concomitant loss of actin stress fibres, protease inhibitor-mediated adhesion reduction may disrupt the Tm5NM1-stabilized actin filaments, thus permitting the reorganization of actin filaments that is required for amoeboid motility. Notably, the Tm5NM1 cells have a distinct morphology (classified in the present study as elliptical) from either classic mesenchymal or amoeboid phenotypes. Others have reported mixed populations of cells including those that similarly cannot be classed morphologically as either mesenchymal or amoeboid Yamazaki et al., 2009) . It is therefore of considerable interest to determine whether such cells may be undergoing a stationary phase.
The derivation of successful new approaches to inhibit cancer cell invasion requires a clear understanding of the processes regulating the switch between different modes of motility. In particular, it is necessary to identify approaches that may be used to block one form of motility without causing a corresponding motility mode transition. In the present study, we have found that elevated expression of the tropomyosin isoform Tm5NM1 robustly inhibits mesenchymal cell migration without causing the transition to amoeboid motility. It will now be of significant interest to determine whether Tm5NM1-mediated stabilization of the actin cytoskeleton and adhesions to the extracellular matrix can hold cells in place and block infiltration in an in vivo tissue context. Consequently, approaches that block active actin filament dynamics may represent an efficient method for arresting the invasion and metastasis of cells that use a mesenchymal mode of motility.
Materials and methods
Cell culture, drugs, plasmids and antibodies The human cell lines HT1080 and U-87 MG; rodent cell line B35; and B35 cell clones overexpressing Tm5NM1 (B35.Tm5NM1) and Tm3 (B35.Tm3) have been previously described (Bryce et al., 2003; Yamazaki et al., 2009) . Characterization of the tropomyosin expression profile of the cells under examination is shown in Supplementary Figure 4 . All cell lines were propagated in 100 mm tissue culture dishes (Corning, New York, NY, USA) in high-glucose Dulbecco 0 s modied Eagle 0 s medium (Invitrogen, Carlsbad, CA, USA) containing 10% Hyclone-fetal bovine serum (Thermo Fisher Scientific, Waltham, MA, USA). The derivation of g-Tm knockout mouse lines and primary mouse embryo fibroblasts (MEF g-9DÀ/À) have been previously described (Fath et al., 2010) . Cells were transiently transfected with cDNA expression plasmids encoding YFP-fused Tm5NM1 (previously described (Percival et al., 2004) ), dominant-negative Rac GTPase (pGFP.RacN17, previously described (Bargon et al., 2005) ) and LifeACT tagged with monomeric GFP to detect filamentous actin (generously provided by Roland Wedlich-Soldner, Max Planck Institute of Biochemistry). Cells were transfected in Optimem media (Invitrogen) using Lipofectamine 2000 (Invitrogen) as per the manufacturer's protocol. The protease inhibitor (PI) cocktail contained E-64 (Sigma, St Louis, MO, USA), Pepstatin A (Sigma), Leupeptin (Sigma), Aprotinin (Sigma) and Marimastat (Tocris Bioscience, Ellisville, MO, USA); concentrations used were those previously described to induce mesenchymal to amoeboid migration . The Rho kinase inhibitor Y-27632 (Sigma) was used at 10 mM, a concentration previously described to inhibit Rho kinase activity (Wyckoff et al., 2006) . Sheep polyclonal anti-g/9d antibody was used to detect exon 9D containing tropomyosins isoforms (Tm5NM1/2), and mouse anti-a/9d antibody was used to detect Tms 1, 2, 3, 5a and 5b as previously described . Anti-HSP70 antibodies (Sigma), anti-Src (Millipore, Billerica, MA, USA), anti-Src pY418 (Invitrogen), horseradish peroxidase-conjugated anti-mouse from Amersham Pharmacia Biotech (GE healthcare, Fairfield, CT, USA) and horseradish peroxidase-conjugated anti-sheep (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) were also used for detection. The in vitro Src kinase assays were performed as per the manufacturer's instructions (Src kinase assay kit Cat.17-131, Millipore), and small interfering RNA (Qiagen, Hilden, Germany)-mediated knockdown of exogenous Tm5NM1 was achieved as previously described (Bach et al., 2009) .
Fluorescence microscopy GFP-LifeACT-labelled B35 control and B35.Tm5NM1 cells were examined using a FluoView FV1000 confocal microscope (Olympus, Walkersville, NY, USA) with a UPLSAPO 60 Â NA1.2 water-immersion lens. GFP was excited with a 473 nm argon laser set at 6%, emission peak set at 510 nm and a 10 ms/ pixel sampling speed. Images were captured at 1024 Â 1024 pixel resolution at 0.6 mm intervals for z-stacking. Quantification of xyz dimensions for calculation of total cell occupancy volume was performed using FluoView V2.0 (Olympus). Images of fixed cell expressing fluorescent proteins were captured using an ORCA ERG cooled CCD camera (Hamamatsu/SDR Clinical Technology, Hamamatsu City, Japan) mounted on an IX81 inverted microscope (Olympus) using Metamorph V7.6 (Molecular Devices, Sunnyvale, CA, USA). Final micrograph images were prepared using Photoshop C2S (Adobe, San Jose, CA, USA). Image quantitation and measurement procedures were carried out using Metamorph V7.6 (Molecular Devices).
3D live cell imaging
For 3D imaging, cells were seeded within rat tail collagen I gels (1.7 mg/ml) (BD Biosciences, San Jose, CA, USA) in 35-mm glass-bottom dishes (MatTek, Ashland, MA, USA) or falcon 24-well plates (BD Biosciences) at B1 Â 10 5 cells/ml. Before imaging, complete media was replaced with CO 2 -independent media (Invitrogen) containing 10% fetal bovine serum (Hyclone) (Thermo Fisher Scientific). Images were captured using an ORCA ERG cooled CCD camera (Hamamatsu/SDR Clinical Technology) mounted on an IX81 inverted microscope (Olympus) equipped with an environmental chamber heated to 37 1C and an X-cite fluorescent light source (EXFO, Quebec, Canada). Time-lapse images were converted into stacks using Metamorph V7.6 (Molecular Devices).
Migration analysis
Random migration analysis was performed on cells seeded at low density within 3D collagen matrices. Cells undergoing obvious mitotic division or apoptosis were excluded. Quantification of cell viability was performed by direct addition of 10 mM propidium iodide to 3D cell cultures 48 h after seeding, followed by bright-field and fluorescent imaging. Viable cells were identified by exclusion of propidium iodide. Quantification of migration was achieved by tracking nuclear translocation in time-lapse stacks using Metamorph V7.6 (Molecular Devices). Average speed was calculated using Excel (Microsoft, Redmond, WA, USA). Stacks of image .tiff files were converted to .AVI files using Metamorph V7.6 (Molecular Devices) and then edited into a final video sequences using Movie Maker (Microsoft). Videos were then converted to MPEG-4 files using Total video converter (OJOsoft, www.ojosoft.com). Cell invasion assays were adapted from a previously described method (Sanz-Moreno et al., 2008) . Approximately 2.5 Â 10 4 cells were seeded within 1.7 mg/ml collagen gel containing o1% serum in 96-well flat bottom plates (100 ml of gel per well). Plates were centrifuged, forcing cells to the bottom of the well, and gel was then polymerized at 37 1C in 5% CO2 for 60 min. Media containing 10% serum was then added to each well (150 ml), and plates were incubated for 96 h with one media change at 24 h. CMRA orange cell tracker (Invitrogen) was added to wells for 60 min and then replaced with 10% serum-containing media for 60 min. Cells were then fixed in 4% paraformaldehyde before observation using a FluoView FV1000 confocal microscope (Olympus) fitted with a UPLSAPO Â 10 lens. Baseline images were taken at the bottom of the well and reference images taken 100 mm above this height. Invasion was calculated by counting the number of cells observed at 100 mm divided by the total number of cells. 3D reconstruction images of cells within gels were obtained using sequential confocal slices taken every 5 mm from the bottom of the well up to until 200 mm into the gel.
Statistical analysis
All error bars on histograms represent the s.e.m. Statistical comparison of two means was performed by using a Student's t-test, calculated using Excel (Microsoft) and comparison of more than two means was performed using one-way analysis of variance with Tukey's multiple comparison test using Prism V4 (GraphPad Software, La Jolla, CA, USA).
